252 related articles for article (PubMed ID: 29952712)
1. Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States.
Ke X; Kavati A; Wertz D; Huang Q; Wang L; Willey VJ; Stephenson JJ; Ortiz B; Paknis B; Bernstein JA; Beck LA
J Manag Care Spec Pharm; 2018 Jul; 24(7):598-606. PubMed ID: 29952712
[TBL] [Abstract][Full Text] [Related]
2. Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.
Eghrari-Sabet J; Sher E; Kavati A; Pilon D; Zhdanava M; Balp MM; Lefebvre P; Ortiz B; Bernstein JA
Allergy Asthma Proc; 2018 May; 39(3):191-200. PubMed ID: 29458456
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria.
Wang L; Ke X; Kavati A; Wertz D; Huang Q; Willey VJ; Stephenson JJ; Ortiz B; Paknis B; Bernstein JA; Beck LA
Curr Med Res Opin; 2018 Jan; 34(1):35-39. PubMed ID: 29064325
[TBL] [Abstract][Full Text] [Related]
4. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
[TBL] [Abstract][Full Text] [Related]
5. Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.
Tharp MD; Bernstein JA; Kavati A; Ortiz B; MacDonald K; Denhaerynck K; Abraham I; Lee CS
JAMA Dermatol; 2019 Jan; 155(1):29-38. PubMed ID: 30427977
[TBL] [Abstract][Full Text] [Related]
6. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
[No Abstract] [Full Text] [Related]
8. Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis.
Deschaseaux C; McSharry M; Hudson E; Agrawal R; Turner SJ
J Manag Care Spec Pharm; 2016 May; 22(5):561-71. PubMed ID: 27123917
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
Walsh JA; Adejoro O; Chastek B; Palmer JB; Hur P
J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
[TBL] [Abstract][Full Text] [Related]
11. Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States.
Williams P; Kavati A; Pilon D; Xiao Y; Zhdanava M; Balp MM; Lefebvre P; Ortiz B; Hernandez-Trujillo V
Allergy Asthma Proc; 2018 May; 39(3):201-211. PubMed ID: 29514728
[TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States.
Williams PV; Kavati A; Pilon D; Xiao Y; Zhdanava M; Balp MM; Lefebvre P; Ortiz B; Hernandez-Trujillo V
Dermatol Ther (Heidelb); 2018 Mar; 8(1):69-83. PubMed ID: 29429043
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence.
Bernstein JA; Kavati A; Tharp MD; Ortiz B; MacDonald K; Denhaerynck K; Abraham I
Expert Opin Biol Ther; 2018 Apr; 18(4):425-448. PubMed ID: 29431518
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials.
Goldstein S; Gabriel S; Kianifard F; Ortiz B; Skoner DP
Ann Allergy Asthma Immunol; 2017 Apr; 118(4):500-504. PubMed ID: 28390587
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
[No Abstract] [Full Text] [Related]
16. Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk.
Lin I; Sung J; Sanchez RJ; Mallya UG; Friedman M; Panaccio M; Koren A; Neumann P; Menzin J
J Manag Care Spec Pharm; 2016 Jun; 22(6):685-98. PubMed ID: 27231796
[TBL] [Abstract][Full Text] [Related]
17. Cost, utilization, and patterns of medication use associated with chronic idiopathic urticaria.
Zazzali JL; Broder MS; Chang E; Chiu MW; Hogan DJ
Ann Allergy Asthma Immunol; 2012 Feb; 108(2):98-102. PubMed ID: 22289728
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria.
Sánchez J; Zakzuk J; Cardona R
J Allergy Clin Immunol Pract; 2018; 6(1):177-182.e1. PubMed ID: 28709817
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
20. Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study.
Kavati A; Zhdanava M; Ortiz B; LeCocq J; Schiffman B; Pilon D; Ching Cheung H; Lefebvre P; Stone BD
Allergy Asthma Proc; 2019 Sep; 40(5):321-328. PubMed ID: 31345280
[No Abstract] [Full Text] [Related]
[Next] [New Search]
